Biolexis Therapeutics Inc. has announced findings from a study of its oral small-molecule GLP-1 agonist, BLX-7006, in a diet-induced obesity model in mice. In the study, BLX-7006 achieved an average weight reduction of 15% over a 28-day period.
Biolexis Therapeutics Inc. is working on developing orally available, small-molecule AMPK activators that have been found to stimulate AMPK activity as well as dose-dependently enhance glucose uptake in human tissue.
Biolexis Therapeutics Inc. has divulged CDK9/cyclin T1 inhibitors reported to be useful for the treatment of cancer, inflammation and autoimmune disease.
Biolexis Therapeutics Inc. has reported the launch of Metabolexis, a new pipeline company developing three targeted oral small molecules for the treatment of obesity and type 2 diabetes.
Researchers from Biolexis Therapeutics Inc. presented the development of a potent and highly selective CDK9 inhibitor, BLX-3030, and its analogues for the treatment of N-Myc and c-Myc-driven cancers.
